[go: up one dir, main page]

AU2002226048A1 - Urotensin-ii receptor antagonists - Google Patents

Urotensin-ii receptor antagonists

Info

Publication number
AU2002226048A1
AU2002226048A1 AU2002226048A AU2604802A AU2002226048A1 AU 2002226048 A1 AU2002226048 A1 AU 2002226048A1 AU 2002226048 A AU2002226048 A AU 2002226048A AU 2604802 A AU2604802 A AU 2604802A AU 2002226048 A1 AU2002226048 A1 AU 2002226048A1
Authority
AU
Australia
Prior art keywords
urotensin
receptor antagonists
antagonists
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002226048A
Inventor
Dashyant Dhanak
Steven D. Knight
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of AU2002226048A1 publication Critical patent/AU2002226048A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2002226048A 2000-12-11 2001-12-05 Urotensin-ii receptor antagonists Abandoned AU2002226048A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25460000P 2000-12-11 2000-12-11
US60254600 2000-12-11
PCT/US2001/047451 WO2002047687A1 (en) 2000-12-11 2001-12-05 Urotensin-ii receptor antagonists

Publications (1)

Publication Number Publication Date
AU2002226048A1 true AU2002226048A1 (en) 2002-06-24

Family

ID=22964900

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002226048A Abandoned AU2002226048A1 (en) 2000-12-11 2001-12-05 Urotensin-ii receptor antagonists

Country Status (5)

Country Link
US (1) US20040039017A1 (en)
EP (1) EP1351688A4 (en)
JP (1) JP2004515530A (en)
AU (1) AU2002226048A1 (en)
WO (1) WO2002047687A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003048154A1 (en) 2001-12-04 2003-06-12 Actelion Pharmaceuticals Ltd 4-(piperidyl- and pyrrolidyl-alkyl-ureido) -quinolines as urotensin ii receptor antagonists
US7875605B2 (en) * 2002-11-28 2011-01-25 Suven Life Sciences Limited N-arylsulfonyl-3-substituted indoles having serotonin receptor affinity, process for their preparation and pharmaceutical composition containing them
ATE427748T1 (en) 2003-09-26 2009-04-15 Actelion Pharmaceuticals Ltd PYRIDINE DERIVATIVES AND THEIR USE AS UROTENSIN II ANTAGONISTS
WO2005040163A1 (en) * 2003-10-28 2005-05-06 Dr. Reddy's Laboratories Ltd Heterocyclic compounds that block the effects of advanced glycation end products (age)
AR051213A1 (en) 2004-10-12 2006-12-27 Actelion Pharmaceuticals Ltd 1- (2- (4-BENCIL-4-HIDROXI-PIPERIDIN-1-IL) -ETIL) -3- (2-METHYL-QUINOLIN-4-IL) -UREA AS A CRYSTALLINE SULFATE SALT
TW200804347A (en) * 2006-01-10 2008-01-16 Janssen Pharmaceutica Nv Urotensin II receptor antagonists
CL2007002097A1 (en) * 2006-07-20 2008-01-18 Smithkline Beecham Corp Compounds derived from pyrrolidine or morpholine antagonists of urotensin ii; pharmaceutical composition comprising said compounds; and its use to treat congestive heart failure, ischemic heart failure, angina, myocardial ischemia, overactive bladder, asthma and / or copd, among others.
US8759342B2 (en) 2006-07-31 2014-06-24 Janssen Pharmaceutica Nv Benzo[1,4]oxazin-3-one, benzo[1,4]thiazin-3-one and quinolin-2-one urotensin II receptor antagonists
WO2008144268A1 (en) * 2007-05-15 2008-11-27 Boehringer Ingelheim International Gmbh Urotensin ii receptor antagonists
WO2010017105A1 (en) 2008-08-02 2010-02-11 Janssen Pharmaceutica N.V. Urotensin ii receptor antagonists
JOP20180131B1 (en) * 2018-12-24 2023-03-28 Univ Of Petra Substituted quinolone compounds, their use in the treatment of cancer, and a method for preparation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6075137A (en) * 1998-01-09 2000-06-13 Smithkline Beecham Corporation Human urotensin II
CA2330564A1 (en) * 1998-04-29 1999-11-04 John Stephen Elder Quinolones used as mrs inhibitors and bactericides
JP2004515507A (en) * 2000-12-11 2004-05-27 スミスクライン・ビーチャム・コーポレイション Urotensin-II receptor antagonist

Also Published As

Publication number Publication date
US20040039017A1 (en) 2004-02-26
EP1351688A4 (en) 2006-01-04
JP2004515530A (en) 2004-05-27
EP1351688A1 (en) 2003-10-15
WO2002047687A1 (en) 2002-06-20

Similar Documents

Publication Publication Date Title
AU2001255798A1 (en) Glucagon antagonists
AU2002341834A1 (en) Antagonists
AU2001269876A1 (en) Heteroarylalkanoic acids as integrin receptor antagonists
AU2001264657A1 (en) Crf receptor antagonists
AU2001234741A1 (en) Integrin antagonists
AU2441801A (en) Urotensin-ii receptor antagonists
AU2002365655A1 (en) 5-ht7 receptor antagonists
AU2001290772A1 (en) Alpha v integrin receptor antagonists
EP1359915A4 (en) Urotensin-ii receptor antagonists
AU2001286409A1 (en) N-methyl-d-aspartate receptor antagonists
AU2002226048A1 (en) Urotensin-ii receptor antagonists
AU2001240021A1 (en) Diazafluorenone il-8 receptor antagonists
AU2001245724A1 (en) Il-8 receptor antagonists
AU6990000A (en) Novel integrin receptor antagonists
AU2002239506A1 (en) Urotensin-ii receptor antagonists
AU2002216079A1 (en) Bombesin receptor antagonists
AU2001243351A1 (en) Il-8 receptor antagonists
AU2001263288A1 (en) Crf receptor antagonists
AU2001249573A1 (en) Chemokine receptor antagonists
AU2001241896A1 (en) Il-8 receptor antagonists
AU2002217095A1 (en) Bombesin receptor antagonists
AU2001253172A1 (en) Il-8 receptor antagonists
AU2001271018A1 (en) Gpr14 antagonist
AU2001223882A1 (en) Receptor
AUPQ563400A0 (en) Novel receptor